This study is about testing a medicine called CVL-231 (also known as emraclidine) for adults with schizophrenia. Schizophrenia is a mental disorder that affects how a person thinks, feels, and behaves. The goal is to check if the medicine is safe and how well people can handle taking it for a long time. To join the study, you must have already been part of a previous study for 6 weeks and have schizophrenia. You must also be stable on your current medication for at least 3 months. You cannot join if you have other major health problems, certain mental health issues, or if you are pregnant or planning to become pregnant.
- Duration: The study involves long-term evaluation.
- Visits: Participants will need to attend trial visits.
- Risks: There are exclusions for certain medical conditions and medications.
The study requires you to stop certain medications before and during the trial. If you have any questions or concerns, it's important to talk to the study team or your doctor.